Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Long-Term Debt Repayments (2017 - 2025)

Plus Therapeutics (PSTV) has disclosed Long-Term Debt Repayments for 10 consecutive years, with $3.7 million as the latest value for Q1 2025.

  • Quarterly Long-Term Debt Repayments rose 821.14% to $3.7 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, down 7.33% year-over-year, with the annual reading at $3.7 million for FY2025, 7.33% down from the prior year.
  • Long-Term Debt Repayments for Q1 2025 was $3.7 million at Plus Therapeutics, up from $3.6 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $3.7 million in Q1 2025, with the low at $402000.0 in Q1 2022.
  • Average Long-Term Debt Repayments over 4 years is $992272.7, with a median of $402000.0 recorded in 2022.
  • The sharpest move saw Long-Term Debt Repayments changed 0.0% in 2023, then surged 821.14% in 2025.
  • Over 4 years, Long-Term Debt Repayments stood at $402000.0 in 2022, then changed by 0.0% to $402000.0 in 2023, then surged by 794.03% to $3.6 million in 2024, then increased by 3.03% to $3.7 million in 2025.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $3.7 million, $3.6 million, and $402000.0 for Q1 2025, Q2 2024, and Q1 2024 respectively.